Humana (NYSE:HUM) Raised to "Buy" at Wall Street Zen

Humana (NYSE:HUM - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Friday.

Other equities analysts also recently issued research reports about the company. Truist Financial set a $280.00 price target on Humana and gave the company a "hold" rating in a research note on Tuesday, June 17th. Guggenheim started coverage on Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price target on shares of Humana in a report on Thursday, May 1st. Robert W. Baird raised their price objective on Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Finally, Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a report on Thursday, May 1st. Sixteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $280.76.

Humana Stock Up 0.8%

Shares of NYSE:HUM traded up $1.92 during trading on Friday, reaching $241.82. 1,755,323 shares of the stock were exchanged, compared to its average volume of 1,822,007. Humana has a 1-year low of $212.45 and a 1-year high of $406.46. The stock has a fifty day moving average of $241.94 and a two-hundred day moving average of $259.43. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The firm has a market cap of $29.18 billion, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 1.81 and a beta of 0.43.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. During the same quarter in the prior year, the company posted $7.23 earnings per share. The business's revenue was up 8.4% on a year-over-year basis. Research analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Institutional investors have recently bought and sold shares of the company. Revolve Wealth Partners LLC purchased a new position in shares of Humana during the 4th quarter valued at $202,000. Atria Wealth Solutions Inc. lifted its holdings in Humana by 21.1% during the fourth quarter. Atria Wealth Solutions Inc. now owns 1,610 shares of the insurance provider's stock valued at $409,000 after purchasing an additional 281 shares during the last quarter. Sigma Planning Corp lifted its holdings in Humana by 122.0% during the fourth quarter. Sigma Planning Corp now owns 1,456 shares of the insurance provider's stock valued at $369,000 after purchasing an additional 800 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Humana by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,316 shares of the insurance provider's stock worth $2,617,000 after purchasing an additional 62 shares during the period. Finally, New York Life Investment Management LLC increased its stake in shares of Humana by 1.1% in the fourth quarter. New York Life Investment Management LLC now owns 18,049 shares of the insurance provider's stock worth $4,579,000 after purchasing an additional 205 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.